The clinical usefulness of routine MRI assessment

International MS Journal

Volumn 17, Issue 2, 2011, Pages 58-62

  Arnold, D L ^a   Stone, L ^b  

^a MCGILL UNIVERSITY   (Canada)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; PLACEBO; RITUXIMAB;

ARTICLE; BRAIN ATROPHY; BRAIN DAMAGE; CONTRAST ENHANCEMENT; DEMYELINATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; IMAGE ANALYSIS; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; RELAPSE; SENSITIVITY AND SPECIFICITY; WHITE MATTER; BRAIN; DIFFUSION WEIGHTED IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROGNOSIS;

BRAIN; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MULTIPLE SCLEROSIS; PROGNOSIS;

EID: 79959692004     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131(Pt 3):808-817.
2. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50(1):121-127.
3. Paty DW, Oger JJ, Kastrukoff LF, Hashimoto SA, Hooge JP, Eisen AA, et al. MRI in the diagnosis of MS: a prospective study with comparison of clincial evaluation, evoked potentials, oligoclonal bonding, and CT. Neurology 1988; 38:180-185.
4. Fazekas F, Offenbacher H, Fuchs S, Schmidt R, Niederkorn K, Horner S, et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected Multiple Sclerosis. Neurology 1988; 38:1822-1825.
5. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58(6):840-846.
6. Tintore M, Rovira A, Rio J, Nos C, Grive E, Sastre-Garriga J, et al. New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 2003; 60(1):27-30.
7. Swanton JK, Fernando K, Dalton CM, Miszkiel KA, Thompson AJ, Plant GT, et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2006; 77(7):830-833.
8. Swanton JK, Rovira A, Tintore M, Altmann DR, Barkhof F, Filippi M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol. 2007; 6(8): 677-686.
9. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Eng J Med 2002; 346(3): 158-664.
10. Paolillo A, Piattella MC, Pantano P, Di Legge S, Caramia F, Russo P, et al. The Relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis. A monthly MRI study after triple-dose gadolinium-DTPA. J Neurol 2004; 251(4):432-439.
11. Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee JC, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59(9):1412-1420.
12. Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999; 353(9157):964-969.
13. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004; 56(4):548-555.
14. Tomassini V, Paolillo A, Russo P, Giugni E, Prosperini L, Gasperini C, et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006; 253(3):287-293.
15. Rio J, Rovira A, Tintore M, Huerga E, Nos C, Tellez N, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler 2008; 14(4):479-484.
16. Prosperini L, Gallo V, Petsas N, Borriello G, Pozzilli C. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 2009; 16(11):1202-1209.
17. Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, et al. MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008; 79(6):646-651.
18. Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, et al. Interferon beta-1b in secondary progressive MS: A combined analysis of the two trials. Neurology 2004; 63(10):1779-1787.
19. Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology. 2001; 57(11):1969-1975.
20. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66(4):460-471.
21. Mellen Center Approaches. Available at: http://my.clevelandclinic.org/multiple_sclerosis_center/education/approaches.aspx. Accessed 1 September 2010.